Azithromycin differentially affects the IL-13-induced expression profile in human bronchial epithelial cells

Area of Science:

• Respiratory medicine
• Molecular biology
• Pharmacology

Background:

• Interleukin-13 (IL-13) drives Th2 responses and airway hyperresponsiveness.
• A Th2 gene signature (POSTN, CLCA1, SERPINB2) is linked to asthma phenotypes.
• Azithromycin's efficacy varies in asthma subtypes, despite reducing IL-13 mucus production.

Purpose of the Study:

• To investigate azithromycin's differential effects on IL-13-induced gene expression in airway epithelial cells.
• To analyze the impact of azithromycin on mucin and Th2 signature gene expression.
• To understand the mechanisms behind azithromycin's varied clinical effects in asthma.

Main Methods:

• Primary human bronchial epithelial cells cultured at air-liquid interface.
• Treatment with IL-13 alone or in combination with azithromycin.
• Analysis of MUC5AC, POSTN, CLCA1, and SERPINB2 gene expression.

Main Results:

• Azithromycin inhibited IL-13-induced MUC5AC, CLCA1, and SERPINB2 expression.
• Azithromycin significantly increased IL-13-induced POSTN expression.
• These findings demonstrate a differential effect of azithromycin on the IL-13-induced Th2 gene signature.

Conclusions:

• Azithromycin exhibits distinct effects on components of the IL-13-induced Th2 gene signature.
• The reduction in MUC5AC by azithromycin may involve decreased CLCA1 expression.
• This differential modulation could explain azithromycin's varied clinical outcomes in different asthma phenotypes.